title: Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.
abstract: Five years of adjuvant tamoxifen treatment has been the gold standard for women with early hormone-responsive breast cancer. Results from two large phase III, adjuvant studies have indicated that the third-generation aro-matase inhibitors (AIs) letrozole and anastrozole offer greater protection against recurrence than tamoxifen in upfront substitution strategies in the first 5 years. Similarly, changeover to an AI (exemestane or anastrozole) after 2-3 years of tamoxifen has been more efficient to prevent recurrence than 5 years of tamoxifen. Most early breast cancer recurrences occur 5 or more years after surgery. Letrozole has been shown to offer greater protection against recurrence than placebo in the 5 years after a standard course of tamoxifen. The optimal adjuvant use (duration and sequencing) of AIs requires further investigation. Safety implications of treatment with these AIs for 5 years or more are closely monitored. The anticipated effects of estrogen deprivation on bone health may be treatable with bisphosphonates. Effects on the cardiovascular system, and other estrogen-sensitive systems such as the central nervous system, are currently examined. The AIs letrozole, anastrozole, and ex-emestane have recently replaced tamoxifen as the recommended adjuvant endocrine therapy, on the basis of greater efficacy and better tolerability.
authors.affiliation: University of Kiel, OB/GYN and Breast Center, Kiel, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Mundhenke
authors.forename: Christian
authors.initials: C
authors.lastname: Schem
authors.forename: Walter
authors.initials: W
authors.lastname: Jonat
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references.pmid: 9747868
references.citation: N Engl J Med. 2004 Mar 11;350(11):1081-92
references.pmid: 15014181
references.citation: Lancet. 2005 Jan 1-7;365(9453):60-2
references.pmid: 15639680
references.citation: Obstet Gynecol Surv. 2004 Jun;59(6):446-55; quiz 485
references.pmid: 15167766
references.citation: J Bone Miner Res. 2002 Jan;17(1):172-8
references.pmid: 11771665
references.citation: Br J Cancer. 1999 Mar;79(7-8):1179-81
references.pmid: 10098755
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2664-70
references.pmid: 17563395
references.citation: Lancet. 2007 Feb 17;369(9561):559-70
references.pmid: 17307102
references.citation: Semin Oncol. 2003 Dec;30(6):763-75
references.pmid: 14663777
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3629-35
references.pmid: 16822845
references.citation: Lancet. 2005 Aug 6-12;366(9484):455-62
references.pmid: 16084253
references.citation: Oncologist. 2004;9(5):489-96
references.pmid: 15477633
references.citation: J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):289-93
references.pmid: 14623523
references.citation: N Engl J Med. 2002 Feb 28;346(9):653-61
references.pmid: 11870242
references.citation: Eur Spine J. 2003 Oct;12 Suppl 2:S132-41
references.pmid: 13680313
references.citation: Ann Oncol. 2005 May;16(5):707-15
references.pmid: 15817595
references.citation: Eur J Cancer. 2005 Aug;41(12):1678-89
references.pmid: 16098456
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Mayo Clin Proc. 2000 Aug;75(8):821-9
references.pmid: 10943237
references.citation: Drugs Aging. 1996 May;8(5):329-37
references.pmid: 8935395
references.citation: N Engl J Med. 2003 Nov 6;349(19):1793-802
references.pmid: 14551341
references.citation: Anticancer Drugs. 1992 Oct;3(5):455-62
references.pmid: 1450438
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5138-47
references.pmid: 16009955
references.citation: J Natl Cancer Inst. 2001 May 2;93(9):684-90
references.pmid: 11333290
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7512-7
references.pmid: 16234518
references.citation: Breast Cancer Res. 2004;6(6):255-7
references.pmid: 15535855
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: BMJ. 1995 Oct 14;311(7011):977-80
references.pmid: 7580638
references.citation: J Clin Oncol. 1996 Jan;14(1):78-84
references.pmid: 8558225
references.citation: Clin Cancer Res. 2004 Sep 1;10(17):5717-23
references.pmid: 15355898
references.citation: J Natl Cancer Inst. 1996 Nov 6;88(21):1510-2
references.pmid: 8901846
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1948-55
references.pmid: 18332475
references.citation: Ann Oncol. 2001 Nov;12(11):1527-32
references.pmid: 11822750
references.citation: Bone. 2004 Mar;34(3):384-92
references.pmid: 15003786
references.citation: J Clin Oncol. 2001 May 15;19(10):2596-606
references.pmid: 11352951
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):614-21
references.pmid: 12101108
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
references.pmid: 16145047
references.citation: Oncologist. 2004;9(2):126-36
references.pmid: 15047917
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2101-9
references.pmid: 12775735
references.citation: J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42
references.pmid: 8901851
references.citation: Breast Cancer Res Treat. 1996;40(3):265-70
references.pmid: 8883969
references.citation: Ann Oncol. 2004 Feb;15(2):211-7
references.pmid: 14760111
references.citation: J Clin Oncol. 2007 Feb 10;25(5):486-92
references.pmid: 17200148
references.citation: Cancer. 2003 Nov 1;98(9):1802-10
references.pmid: 14584060
references.citation: Cancer. 2004 Sep 15;101(6):1311-22
references.pmid: 15368322
references.citation: J Clin Oncol. 2000 Apr;18(7):1570-93
references.pmid: 10735906
references.citation: J Clin Oncol. 1996 Oct;14(10):2738-46
references.pmid: 8874335
references.citation: J Clin Oncol. 2003 Nov 1;21(21):4042-57
references.pmid: 12963702